SynthesisGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2022
Cardiometabolic factors and risk of non-arteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis.
Synthesis in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Pooled it
- Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.JAMA ophthalmology · 2025Pooled it
- Diagnostic significance of neutrophil-to-lymphocyte ratio in non-arteritic anterior ischemic optic neuropathy: a meta-analysis.European journal of medical research · 2024Pooled it
- Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype.Diabetes, obesity & metabolism · 2026Review
- Optic disc drusen prevalence and visual outcome in a cohort of patients with non-arteritic anterior ischemic optic neuropathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Risk factor profiles and visual outcomes of non-arteritic anterior ischemic optic neuropathy in younger Chinese patients.BMC ophthalmology · 2026Article
- Development of a predictive model for visual outcomes and risk factors of bilateral involvement for non-arteritic anterior ischemic optic neuropathy (NAION) in Chinese patients.Eye and vision (London, England) · 2026Article
- Pathogenesis of Non-Arteritic Anterior Ischemic Optic Neuropathy Associated with COVID-19.International journal of molecular sciences · 2026Review
- Orbital MRI for diagnosing giant cell arteritis in cases of anterior ischaemic optic neuropathy.RMD open · 2026Article
- Machine learning prediction models for visual impairment in Chinese adults aged ≥ 45 years with cardiovascular metabolic diseases: a population-based study using CHARLS.BMC ophthalmology · 2025Article
- Anterior Ischemic Optic Neuropathy as a Paraneoplastic Manifestation of Colorectal Cancer.Cureus · 2025Article
- [Anterior ischemic optic neuropathy (AION) : S1 guidelines of the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Version: 30.08.2024].Die Ophthalmologie · 2025Review
- Risk factors of developing non-arteric ischemic optic neuropathy in patients with type 2 diabetes mellitus: a single-center retrospective cohort study.International journal of ophthalmology · 2025Article
- Advances in materials science for ocular diseases induced by cardiovascular risk factors.Frontiers in bioengineering and biotechnology · 2025Review
- Evaluation and management of nonarteritic anterior ischemic optic neuropathy: a national survey.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia.JAMA network open · 2024Article
- Predictive effect of nonarteritic anterior ischemic optic neuropathy on the development of cerebral small vessel disease: a retrospective study.Frontiers in neurology · 2024Article
- Hypoperfusion states could increase the risk of non-arteritic anterior ischemic optic neuropathy.PloS one · 2024Article
- Altered functional connectivity of the default mode network in non-arteritic anterior ischaemic optic neuropathy.Brain communications · 2024Article
- Non-arteritic Anterior Ischemic Optic Neuropathy Sequela From Potential COVID-19-Associated Coagulopathy.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this systematic review and meta-analysis of the literature is to evaluate the association between cardiometabolic risk factors (hypertension, diabetes mellitus, hypercholesterolemia/dyslipidemia, HDL cholesterol, LDL cholesterol, lipoprotein(a), and triglycerides) and non-arteritic anterior ischemic optic neuropathy (NAION).
methodsPertinent publications were identified through a systematic search in PubMed and EMBASE databases, without language restrictions. The pooled odds ratios (OR) and standardized mean differences (SMD), with their 95% confidence intervals (95% CI) were estimated using random effects (DerSimonian Laird) models, as appropriate. A set of subgroup analyses and meta-regression analysis models were performed.
resultsTwenty-one studies (including 1560 patients with NAION and 2292 controls), examining the association between NAION and cardiometabolic risk factors, were eligible for the systematic review and meta-analysis. Hypertension (pooled OR = 1.50; 95% CI: 1.16-1.94), diabetes mellitus (pooled OR = 1.71; 95% CI: 1.33-2.21), and hypercholesterolemia/dyslipidemia (pooled OR = 2.00; 95% CI: 1.53-2.62) were associated with NAION. Among the components of dyslipidemia, higher serum triglycerides were associated with NAION, with a medium effect size (SMD = + 0.58, 95% CI: + 0.12 to + 1.04), whereas synthesis of four studies reporting on HDL and LDL cholesterol did not reveal any significant associations. A significant association between NAION and higher serum lipoprotein(a) levels (pooled OR = 2.88; 95%CI: 1.01-8.21) was also noted.
conclusionsThis systematic review and meta-analysis found that NAION was associated with cardiometabolic factors, suggesting that vascular dysfunction may be implicated in the pathogenesis of the disease. Our findings may alert health care providers to try modifying these risk factors for NAION prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.